Hoth Therapeutics 因患者需求增加,增设新临床中心加速 HT-001 试验入组

美股速递
Feb 25

随着患者需求显著上升,Hoth Therapeutics 正通过增设新的临床研究中心,全力加快其核心候选药物 HT-001 的临床试验患者入组进程。

这一战略举措旨在高效应对日益增长的患者参与意愿,确保试验能够按计划甚至提前推进,从而为后续的药物开发奠定坚实基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10